Cargando…
Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be related to the occurrence of complications, including graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is connected with T lymphocytes, which identify alloantigens on host's antigen-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521416/ https://www.ncbi.nlm.nih.gov/pubmed/36187719 http://dx.doi.org/10.4331/wjbc.v13.i4.72 |
_version_ | 1784799832045518848 |
---|---|
author | Rybicka-Ramos, Malwina Markiewicz, Mirosław Suszka-Świtek, Aleksandra Wiaderkiewicz, Ryszard Mizia, Sylwia Dzierżak-Mietła, Monika Białas, Krzysztof |
author_facet | Rybicka-Ramos, Malwina Markiewicz, Mirosław Suszka-Świtek, Aleksandra Wiaderkiewicz, Ryszard Mizia, Sylwia Dzierżak-Mietła, Monika Białas, Krzysztof |
author_sort | Rybicka-Ramos, Malwina |
collection | PubMed |
description | BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be related to the occurrence of complications, including graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is connected with T lymphocytes, which identify alloantigens on host's antigen-presenting cells, activate production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), and act on the immune effector cells and damage tissues and organs. AIM: The aim of the study was to investigate and distinguish serum concentration profiles of IFN-gamma and IL-2 within a 30-d period after allo-HSCT. METHODS: We enrolled 62 patients, i.e., 30 (48%) male and 32 (52%) female subjects [median age 49.5 (19-68) years], after allo-HSCT from siblings (n = 12) or unrelated donors (n = 50) due to acute myeloid leukemia with myeloablative conditioning (n = 26; 42%) and with non-myeloablative conditioning (n = 36; 58%). All patients were given standard immunosuppressive therapy with cyclosporin-A and methotrexate and pre-transplant antithymocyte globulin in the unrelated setting. Blood samples were collected pre-transplant before and after (on day -1) the conditioning therapy and on days +2,+4, +6, +10, +20, and +30 after allo-HSCT. Serum levels of IL-2 and IFN-gamma were determined using ELISA. RESULTS: Patients were divided into four groups depending on the presence of acute GvHD and clinical manifestations of infection. Group I included patients with neither acute GvHD nor infections [n = 15 (24%)], group II consisted of patients with infections without acute GvHD [n = 17 (27%)], group III was comprised of patients with acute GvHD without infections [n = 9 (15%)], and group IV included patients with both acute GvHD and infections [n = 21 (34%)]. IFN-gamma concentrations were higher in Group II than in other groups on days +20 (P = 0.014) and +30 (P = 0.008). Post-hoc tests showed lower concentrations of IFN-gamma on day +30 in groups I (P = 0.039) and IV (P = 0.017) compared to group II. The levels of IL-2 were mostly undetectable. CONCLUSION: Serum levels of IFN-gamma following allo-HSCT progressively escalate. High serum levels of IFN-gamma are related to infectious complications rather than acute GvHD. Serum concentrations of IL-2 in most patients are undetectable. |
format | Online Article Text |
id | pubmed-9521416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-95214162022-09-30 Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation Rybicka-Ramos, Malwina Markiewicz, Mirosław Suszka-Świtek, Aleksandra Wiaderkiewicz, Ryszard Mizia, Sylwia Dzierżak-Mietła, Monika Białas, Krzysztof World J Biol Chem Basic Study BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be related to the occurrence of complications, including graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is connected with T lymphocytes, which identify alloantigens on host's antigen-presenting cells, activate production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), and act on the immune effector cells and damage tissues and organs. AIM: The aim of the study was to investigate and distinguish serum concentration profiles of IFN-gamma and IL-2 within a 30-d period after allo-HSCT. METHODS: We enrolled 62 patients, i.e., 30 (48%) male and 32 (52%) female subjects [median age 49.5 (19-68) years], after allo-HSCT from siblings (n = 12) or unrelated donors (n = 50) due to acute myeloid leukemia with myeloablative conditioning (n = 26; 42%) and with non-myeloablative conditioning (n = 36; 58%). All patients were given standard immunosuppressive therapy with cyclosporin-A and methotrexate and pre-transplant antithymocyte globulin in the unrelated setting. Blood samples were collected pre-transplant before and after (on day -1) the conditioning therapy and on days +2,+4, +6, +10, +20, and +30 after allo-HSCT. Serum levels of IL-2 and IFN-gamma were determined using ELISA. RESULTS: Patients were divided into four groups depending on the presence of acute GvHD and clinical manifestations of infection. Group I included patients with neither acute GvHD nor infections [n = 15 (24%)], group II consisted of patients with infections without acute GvHD [n = 17 (27%)], group III was comprised of patients with acute GvHD without infections [n = 9 (15%)], and group IV included patients with both acute GvHD and infections [n = 21 (34%)]. IFN-gamma concentrations were higher in Group II than in other groups on days +20 (P = 0.014) and +30 (P = 0.008). Post-hoc tests showed lower concentrations of IFN-gamma on day +30 in groups I (P = 0.039) and IV (P = 0.017) compared to group II. The levels of IL-2 were mostly undetectable. CONCLUSION: Serum levels of IFN-gamma following allo-HSCT progressively escalate. High serum levels of IFN-gamma are related to infectious complications rather than acute GvHD. Serum concentrations of IL-2 in most patients are undetectable. Baishideng Publishing Group Inc 2022-09-27 2022-09-27 /pmc/articles/PMC9521416/ /pubmed/36187719 http://dx.doi.org/10.4331/wjbc.v13.i4.72 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Rybicka-Ramos, Malwina Markiewicz, Mirosław Suszka-Świtek, Aleksandra Wiaderkiewicz, Ryszard Mizia, Sylwia Dzierżak-Mietła, Monika Białas, Krzysztof Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title | Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title_full | Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title_fullStr | Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title_full_unstemmed | Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title_short | Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
title_sort | profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521416/ https://www.ncbi.nlm.nih.gov/pubmed/36187719 http://dx.doi.org/10.4331/wjbc.v13.i4.72 |
work_keys_str_mv | AT rybickaramosmalwina profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT markiewiczmirosław profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT suszkaswitekaleksandra profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT wiaderkiewiczryszard profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT miziasylwia profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT dzierzakmietłamonika profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation AT białaskrzysztof profilesofinterferongammaandinterleukin2inpatientsafterallogeneichematopoieticstemcelltransplantation |